BioSpace News Archive

MetroHealth and Medical Mutual are first to go live with new software solution; increasing collaboration and accelerating processes while reducing costs

New board officers, Chairs of Subspecialty Divisions, and Subspecialty Division Members for The American Board of Obstetrics and Gynecology (ABOG) officially started their new appointments on July 1.

A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows.

For the first-time, researchers at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences - develop organoids, that mimic the onset of brain cancer.

FzioMed is pleased to announce the enrollment of patient number one in the supportive study of Oxiplex® in patients undergoing lumbar surgery for disc herniation

Rowley Law PLLC is investigating potential claims against LifePoint Health, Inc. (NASDAQ: LPNT) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Apollo Global Management.

By focusing on younger women with breast cancer, researchers were able to shed new light on the risks presented by residual disease for this population, regardless of affected site

Ronald D. Alvarez, MD, MBA, was elected to Director-At-Large member of the Board of Directors for the American Board of Obstetrics and Gynecology (ABOG) at the June 2018 Board of Directors meeting.

In a new study published in Nutrients titled “Lutein and Zeaxanthin Isomers Protect Against Light-induced Retinopathy via Decreasing Oxidative and Endoplasmic Reticulum Stress in BALB/cJ Mice,” Lutemax 2020 supplementation was shown to protect photoreceptors against blue light damage by mitigating oxidative and endoplasmic reticulum stress

Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, announced the publication of preclinical data demonstrating the potential of CLT030,the Company’s CLL1-targeting...